When would an Investigational New Drug Application (IND) be submitted?

When would an Investigational New Drug Application (IND) be submitted?

• A. after market approval
• B. To begin clinical tests or transport new drugs across state lines
• C. To request expedited approval
• D. To license manufacturing facilities

Answer: (B)

The main idea tested is when an Investigational New Drug (IND) is needed: it is filed to start testing a new drug in humans and to allow the drug to be shipped across state lines to trial sites. This is the required FDA permission that precedes any clinical study, ensuring safety and regulatory oversight of preclinical data, study protocols, and manufacturing information before people are exposed to the drug. This isn’t about post-approval activities (that would be licensing for marketing), expedited approval pathways (which occur after development and during regulatory review), or licensing manufacturing facilities (which concerns GMP compliance and facility authorization). The IND specifically enables clinical investigations and interstate shipment of an unapproved drug for those studies.

The main idea tested is when an Investigational New Drug (IND) is needed: it is filed to start testing a new drug in humans and to allow the drug to be shipped across state lines to trial sites. This is the required FDA permission that precedes any clinical study, ensuring safety and regulatory oversight of preclinical data, study protocols, and manufacturing information before people are exposed to the drug.

This isn’t about post-approval activities (that would be licensing for marketing), expedited approval pathways (which occur after development and during regulatory review), or licensing manufacturing facilities (which concerns GMP compliance and facility authorization). The IND specifically enables clinical investigations and interstate shipment of an unapproved drug for those studies.